

16 **Background:** SARS-CoV-2 shedding dynamics in the upper (URT) and lower respiratory tract
17 (LRT) remain unclear.

18

19 **Objective:** To analyze SARS-CoV-2 shedding dynamics across COVID-19 severity, the
20 respiratory tract, sex and age cohorts (aged 0 to 17 years, 18 to 59 years, and 60 years or older).

21

22 **Design:** Systematic review and pooled analyses.

23

24 **Setting:** MEDLINE, EMBASE, CENTRAL, Web of Science Core Collection, medRxiv and
25 bioRxiv were searched up to 20 November 2020.

26

27 **Participants:** The systematic dataset included 1,266 adults and 136 children with COVID-19.

28

29 **Measurements:** Case characteristics (COVID-19 severity, age and sex) and quantitative
30 respiratory viral loads (rVLs).

31

32 **Results:** In the URT, adults with severe COVID-19 had higher rVLs at 1 DFSO than adults ($P =$
33 0.005) or children ($P = 0.017$) with nonsevere illness. Between 1-10 DFSO, severe adults had
34 comparable rates of SARS-CoV-2 clearance from the URT as nonsevere adults ($P = 0.479$) and
35 nonsevere children ($P = 0.863$). In the LRT, severe adults showed higher post-symptom-onset
36 rVLs than nonsevere adults ($P = 0.006$). In the analyzed period (4-10 DFSO), severely affected
37 adults had no significant trend in SARS-CoV-2 clearance from LRT ($P = 0.105$), whereas

38 nonsevere adults showed a clear trend ($P < 0.001$). After stratifying for disease severity, sex and
39 age (including child vs. adult) were not predictive of the duration of respiratory shedding.

40

41 **Limitation:** Limited data on case comorbidities and few samples in some cohorts.

42

43 **Conclusion:** High, persistent LRT shedding of SARS-CoV-2 characterized severe COVID-19 in
44 adults. After symptom onset, severe cases tended to have higher URT shedding than their
45 nonsevere counterparts. Disease severity, rather than age or sex, predicted SARS-CoV-2
46 kinetics. LRT specimens should more accurately prognosticate COVID-19 severity than URT
47 specimens.

48

49 **Primary Funding Source:** Natural Sciences and Engineering Research Council.

50 INTRODUCTION

51 As of 17 February 2021, the coronavirus disease 2019 (COVID-19) pandemic has caused more
52 than 109 million infections and 2.4 million deaths globally (1). The clinical spectrum of COVID-
53 19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is wide, ranging
54 from asymptomatic infection to fatal disease. Risk factors for severe illness and death include
55 age, sex, smoking and comorbidities, such as obesity, hypertension, diabetes and cardiovascular
56 disease (2-4). Emerging evidence indicates that age and sex differences in innate, cross-reactive
57 and adaptive immunity facilitate the higher risks in older and male cases (5-8). Robust immune
58 responses putatively mediate nonsevere illness, in part, by controlling the replication of SARS-
59 CoV-2 (9).

60 As SARS-CoV-2 is a respiratory virus, its shedding dynamics in the upper (URT) and lower
61 respiratory tract (LRT) provide insight into clinical and epidemiological factors. URT viral load
62 has been associated with transmission risk, duration of infectiousness, disease severity and
63 mortality (10-16). Key questions, however, remain. While chest computed tomography (CT)
64 evidence of viral pneumonitis suggests pulmonary replication in most symptomatic cases (17),
65 the LRT kinetics of SARS-CoV-2, especially as related to disease severity, remain unknown.
66 The relationships between sex, age and disease severity on respiratory shedding are unclear.
67 Moreover, whether children clear SARS-CoV-2 at similar rates as adults, and if this correlates
68 the age-based differences in disease severity, is unknown.

69 For insight into these questions, we conducted a systematic review on SARS-CoV-2
70 quantitation from respiratory specimens and developed a large, diverse dataset of respiratory
71 viral loads (rVLs) and individual case characteristics. Stratified pooled analyses then assessed
72 SARS-CoV-2 shedding dynamics across the respiratory tract, age, sex and COVID-19 severity.

73

74 **METHODS**

75 Our systematic review identified studies reporting SARS-CoV-2 quantitation in respiratory
76 specimens taken during the estimated infectious period (-3 to 10 days from symptom onset
77 [DFSO]) (15, 18). The systematic review protocol was based on our previous study (19) and was
78 prospectively registered on PROSPERO (registration number, CRD42020204637). The
79 systematic review was conducted according to Cochrane methods guidance (20). Other than the
80 title of this study, we have followed PRISMA reporting guidelines (21).

81

82 **Data Sources and Searches**

83 Up to 20 November 2020, we searched, without the use of filters or language restrictions,
84 the following sources: MEDLINE (Ovid), EMBASE (Ovid), Cochrane Central Register of
85 Controlled Trials (CENTRAL, Ovid), Web of Science Core Collection, and medRxiv and
86 bioRxiv (both searched through Google Scholar via the Publish or Perish program). We also
87 gathered studies by searching through the reference lists of review articles identified by the
88 database search, by searching through the reference lists of included articles, through expert
89 recommendation (by Epic J. Topol and Akiko Iwasaki on Twitter) and by hand-searching
90 through journals. A comprehensive search was developed by a librarian (Z.P.). Additional details
91 on the search are included in the **Supplement**.

92

93 **Study selection**

94 Studies that reported SARS-CoV-2 quantitation in individual URT (nasopharyngeal swab
95 [NPS], nasopharyngeal aspirate [NPA], oropharyngeal swab [OPS] or posterior oropharyngeal

96 saliva [POS]) or LRT (endotracheal aspirate [ETA] or sputum [Spu]) specimens taken during the
97 estimated infectious period (-3 to 10 DFSO) in humans were included (additional details in the
98 **Supplement**). As semiquantitative metrics (cycle threshold [Ct] values) cannot be compared on
99 an absolute scale between studies based on instrument and batch variation (22), studies reporting
100 specimen measurements as Ct values, without quantitative calibration, were excluded. Two
101 authors (P.Z.C. and N.B.) independently screened titles and abstracts and reviewed full texts. At
102 the full-text stage, reference lists were reviewed for study inclusion. Inconsistencies were
103 resolved by discussion and consensus.

104

105 **Data Extraction and Risk-of-Bias Assessment**

106 Two authors (P.Z.C. and N.B.) independently collected data (specimen measurements taken
107 between -3 and 10 DFSO, specimen type, volume of transport media and case characteristics,
108 including age, sex and disease severity) from contributing studies and assessed risk of bias using
109 a modified Joanna Briggs Institute (JBI) critical appraisal checklist (described in the
110 **Supplement** and shown in **Supplement Table 6**). Data were collected for individually reported
111 specimens of known type, with known DFSO, and for COVID-19 cases with known age, sex or
112 severity. Case characteristics were collected directly from contributing studies when reported
113 individually or obtained via data request from the authors. Data from serially sampled
114 asymptomatic cases were included, and the day of laboratory diagnosis was referenced as 0
115 DFSO (15, 23). Based on the modified JBI checklist, studies were considered to have low risk of
116 bias if they met the majority of items and included item 1 (representative sample). Discrepancies
117 were resolved by discussion and consensus.

118

119 **Respiratory Viral Load**

120 For analyses based on rVL (viral RNA concentration in the respiratory tract) and to account
121 for interstudy variation in the volumes of viral transport media (VTM) used, the rVL for each
122 collected sample was estimated based on the specimen concentration (viral RNA concentration
123 in the specimen) and dilution factor in VTM. Typically, swabbed specimens (NPS and OPS)
124 report the viral RNA concentration in VTM. Based on the VTM volume reported in the study
125 along with the expected uptake volume for swabs (0.128 ± 0.031 ml, mean \pm SD) (24), we
126 calculated the dilution factor for each respiratory specimen and then estimated the rVL.
127 Similarly, liquid specimens (ETA, POS and Spu) are often diluted in VTM, and the rVL was
128 estimated based on the reported collection and VTM volumes. If the diluent volume was not
129 reported, then VTM volumes of 1 ml (NPS and OPS) or 2 ml (POS and ETA) were assumed (23,
130 25). Unless dilution was reported, Spu specimens were taken as undiluted (15). The non-
131 reporting of VTM volume was noted as an element increasing risk of bias in the modified JBI
132 critical appraisal checklist. For laboratory-confirmed COVID-19 cases, negative specimen
133 measurements were taken at the reported assay detection limit in the respective study.

134

135 **Case Definitions**

136 As severity in the clinical manifestations of COVID-19 and case-fatality rates tend to
137 increase among children (aged 0-17 y), younger adults (aged 18-59 y) and older adults (aged 60
138 y or older) (4, 26), the data were delineated based on these three age cohorts. Cases were also
139 categorized by sex.

140 U.S. National Institutes of Health guidance was used to categorize disease severity as
141 nonsevere or severe (27). The nonsevere cohort included those with asymptomatic infection

142 (individuals who test positive via a molecular test for SARS-CoV-2 and report no symptoms
143 consistent with COVID-19); mild illness (individuals who report any signs or symptoms of
144 COVID-19, including fever, cough, sore throat, malaise, headache, muscle pain, nausea,
145 vomiting, diarrhea, loss of taste and smell, but who do not have dyspnea or abnormal chest
146 imaging); and moderate illness (individuals with clinical or radiographic evidence of LRT
147 disease, fever $>39.4^{\circ}\text{C}$ or $\text{SpO}_2 \geq 94\%$ on room air) disease. The severe cohort included those
148 with severe illness (individuals who have $\text{SpO}_2 < 94\%$ on room air, $[\text{PaO}_2/\text{FiO}_2] < 300$ mmHg,
149 respiratory rate > 30 breaths/min or lung infiltrates $> 50\%$) and critical illness (respiratory failure,
150 septic shock or multiple organ dysfunction).

151

152 **Statistical Analysis**

153 We used regression analysis to assess the respiratory shedding of SARS-CoV-2 and compare
154 age, sex or severity cohorts. In COVID-19 cases, rVL tends to diminish exponentially after 1
155 DFSO in the URT, whereas it tends to do so after 4 DFSO in the LRT (15, 17, 19). Hence, rVLs
156 (in units of \log_{10} copies/ml) between 1-10 DFSO for the URT, or 4-10 DFSO for the LRT, were
157 fitted using general linear regression with interaction:

$$158 \quad V = \alpha + \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_1 X_2, \quad (1)$$

159 where V represents the rVL, α represents the estimated mean rVL (at 1 DFSO for URT or 4
160 DFSO for LRT) for the reference cohort, X_1 represents DFSO for the reference cohort, X_2
161 represents the comparison cohort, β_1 represents the effect of DFSO on rVL for the reference
162 cohort, β_2 represents the effect of the comparison cohort on the intercept and β_3 represents the
163 interaction between DFSO and cohorts. Regression analyses were offset by DFSO such that
164 mean rVLs at 1 DFSO for URT, or 4 DFSO for LRT, were compared between cohorts by the

165 effect on the intercept (regression t -test for β_2). Shedding dynamics were compared between
166 cohorts by interaction (regression t -test for β_3). The statistical significance of viral clearance for
167 each cohort was analyzed using simple linear regression (regression t -test on the slope).
168 Regression models were extrapolated (to 0 log₁₀ copies/ml, rather than an assay detection limit)
169 to estimate the duration of shedding.

170 To assess heterogeneity in shedding, rVL data were fitted to Weibull distributions (19), and
171 the rVL at a case percentile was estimated using the Weibull quantile function. Each cohort in
172 statistical analyses included all rVLs for which the relevant characteristic (LRT or URT, age
173 cohort, sex or disease severity) was ascertained at the individual level. Cohorts with small
174 sample sizes were not compared, as these analyses are more sensitive to potential sampling error.
175 Statistical analyses were performed using OriginPro 2019b (OriginLab) and the General Linear
176 regression app or Matlab R2019b (MathWorks) and the Distribution Fitter app. P values below
177 0.05 were considered statistically significant.

178

179 **Role of the Funding Source**

180 This study was funded by the Natural Science Research Council of Canada (NSERC). The
181 funder had no role in study design, collection or interpretation of the data, preparation of the
182 manuscript, or the decision to submit the manuscript for publication.

183

184 **RESULTS**

185 **Overview of Contributing Studies**

186 After screening and full-text review, 26 studies met the inclusion criteria and contributed to
187 the systematic dataset (**Figure 1**) (15, 16, 23, 25, 26, 28-48). We collected 1,915 quantitative

188 specimen measurements of SARS-CoV-2 from 1,402 COVID-19 cases (**Table 1**, rVL data
189 summarized in **Appendix Figure**). For pediatric cases, the search found only nonsevere
190 infections and URT specimen measurements. **Appendix Table 1** summarizes the characteristics
191 of contributing studies, of which 18 had low risk of bias according to the modified JBI critical
192 appraisal checklist. Studies at high or unclear risk of bias typically included samples that were
193 not representative of the target population; did not report the VTM volume used; had non-
194 consecutive inclusion for case series and cohort studies or did not use probability-based sampling
195 for cross-sectional studies; and did not report the response rate (**Appendix Table 2**).

196

197 **URT Shedding of SARS-CoV-2 for Adult COVID-19**

198 In the adult URT, regression analysis showed that, at 1 DFSO, the mean rVL for severe
199 COVID-19 (8.28 [95% CI, 7.71-8.84] log₁₀ copies/ml) was significantly greater (*P* for intercept
200 = 0.005) than that of nonsevere COVID-19 (7.45 [95% CI, 7.26-7.65] log₁₀ copies/ml) (**Figure**
201 **2A**). Meanwhile, these cohorts showed comparable rates of SARS-CoV-2 clearance from the
202 URT (*P* for interaction = 0.479). For severe cases, the estimated mean duration of URT shedding
203 (down to 0 log₁₀ copies/ml) was 27.5 (95% CI, 21.2-33.8) DFSO; it was 27.9 (95% CI, 24.4-
204 31.3) DFSO for nonsevere cases.

205 While regression analysis compared mean shedding levels and dynamics, we fitted rVLs to
206 Weibull distributions to assess heterogeneity in shedding. Both severe and nonsevere adult
207 COVID-19 showed comparably broad heterogeneity in URT shedding throughout disease course
208 (**Figure 2B**). For severe disease, the standard deviation (SD) of rVL was 1.86, 2.34, 1.89 and
209 1.90 log₁₀ copies/ml at 2, 4, 7 and 10 DFSO, respectively. For nonsevere illness, these SDs were
210 2.08, 1.90, 1.89 and 1.96 log₁₀ copies/ml, respectively.

211 Based on our data, the distinction in rVL between severity cohorts was greater near
212 symptom onset. Based on distribution fitting (**Figure 2B**), at 2 DFSO, the estimated rVL at the
213 80th case percentile (cp) for severe disease was 9.54 (95% CI, 8.78-10.4) log₁₀ copies/ml, while it
214 was 8.84 (95% CI, 8.49-9.20) log₁₀ copies/ml for nonsevere illness. By 10 DFSO, this difference
215 reduced: the 80th-cp estimates were 6.86 (95% CI, 6.20-7.59) and 6.45 (95% CI, 5.91-7.04) log₁₀
216 copies/ml for severe and nonsevere disease, respectively.

217 After stratifying adults for disease severity, our analyses showed nonsignificant differences
218 in URT shedding based on sex and age. For nonsevere illness, male and female cases had no
219 significant difference in mean rVL at 1 DFSO (P for intercept = 0.085) or rate of viral clearance
220 (P for interaction = 0.644) (**Figure 2C**). Similarly, for severe disease, male and female cases had
221 comparable mean rVLs at 1 DFSO (P for intercept = 0.326) and URT dynamics (P for
222 interaction = 0.280) (**Figure 2D**). For nonsevere illness, younger and older adults had no
223 significant difference in URT shedding levels at 1 DFSO (P for intercept = 0.294) or post-
224 symptom-onset dynamics (P for interaction = 0.100) (**Figure 2E**). For severe disease, the adult
225 age cohorts showed similar mean rVLs at 1 DFSO (P for intercept = 0.915) and rates of viral
226 clearance (P for interaction = 0.359) (**Figure 2F**).

227

228 **LRT Shedding of SARS-CoV-2 for Adult COVID-19**

229 Our analyses showed that high, persistent LRT shedding of SARS-CoV-2 was associated
230 with severe COVID-19, but not nonsevere illness, in adults (**Figure 3A**). At the initial day in our
231 analyzed period (4 DFSO), the mean rVL in the LRT of severe cases (8.42 [95% CI, 7.67-9.17]
232 log₁₀ copies/ml) was significantly greater (P for intercept = 0.006) than that of nonsevere cases
233 (6.82 [95% CI, 5.95-7.69] log₁₀ copies/ml). Between severities, the difference in LRT clearance

234 rates was marginally above the threshold for statistical significance (P for interaction = 0.053).
235 However, severe cases had persistent LRT shedding, with no significant trend in SARS-CoV-2
236 clearance in the analyzed period (-0.14 [95% CI, -0.32 to 0.030] \log_{10} copies/ml day⁻¹, $P =$
237 0.105), whereas nonsevere cases rapidly cleared the virus from the LRT (-0.41 [95% CI, -0.64 to
238 -0.19] \log_{10} copies/ml day⁻¹, $P < 0.001$). For nonsevere cases, the estimated mean duration of
239 LRT shedding (down to 0 \log_{10} copies/ml) was 20.4 (95% CI, 13.2-27.7) DFSO.

240 Accordingly, the distributions of severe and nonsevere LRT shedding bifurcated along
241 disease course (**Figure 3B**). At 6 DFSO, the 80th cp estimate of LRT rVL was 9.40 (95% CI,
242 8.67-10.20) \log_{10} copies/ml for severe COVID-19, while it was 7.66 (95% CI, 6.65-8.83) \log_{10}
243 copies/ml for nonsevere illness. At 10 DFSO, the difference between 80th-cp estimates expanded,
244 as they were 8.63 (95% CI, 8.04-9.26) and 6.01 (95% CI, 4.65-7.78) \log_{10} copies/ml for severe
245 and nonsevere disease, respectively.

246 Our data indicated that nonsevere illness yielded greater skewing in LRT shedding than
247 severe disease in the analyzed period (**Figure 3B**). For nonsevere COVID-19, the SD of rVL was
248 1.92, 2.01 and 2.09 \log_{10} copies/ml at 6, 8 and 10 DFSO, respectively. For severe disease, it was
249 lesser 1.25, 1.37 and 1.61 \log_{10} copies/ml at 6, 8 and 10 DFSO, respectively.

250 For severe COVID-19, regression analysis showed, in the LRT, comparable mean rVLs at 4
251 DFSO between younger and older adults (P for intercept = 0.745) (**Figure 3C**). Both severe age
252 cohorts also showed persistent LRT shedding in the analyzed period: younger adults (-0.20 [95%
253 CI, -0.32 to 0.042] \log_{10} copies/ml day⁻¹, $P = 0.105$) and older adults (-0.13 [95% CI, -0.39 to
254 0.13] \log_{10} copies/ml day⁻¹, $P = 0.316$) both had no significant trend in SARS-CoV-2 clearance.
255 Likewise, severely affected male cases had no significant trend in LRT shedding (0.001 [95%

256 CI, -0.16 to 0.19] \log_{10} copies/ml day⁻¹, $P = 0.988$). The female cohort included few samples, and
257 statistically analyses were not conducted (**Appendix Table 3**).

258 Interestingly, nonsevere cases showed similar SARS-CoV-2 shedding between the URT and
259 LRT, whereas severe cases shed greater and longer in the LRT than the URT (**Figure 3, D and**
260 **E**). At 4 DFSO, the URT rVL of nonsevere adults was 6.62 (95% CI, 6.50-6.74) \log_{10} copies/ml,
261 which was not different from the LRT rVL of nonsevere adults (P for intercept = 0.651). In
262 contrast, at 4 DFSO, the URT rVL of severe adults (7.34 [95% CI, 7.01-7.68] \log_{10} copies/ml)
263 was significantly lower than the LRT rVL of severe adults (P for intercept = 0.031).

264

265 **Comparison of URT Shedding between Adult and Pediatric COVID-19**

266 For the pediatric cohort, regression estimated, in the URT, the mean rVL at 1 DFSO to be
267 7.32 (95% CI, 6.78-7.86) \log_{10} copies/ml and SARS-CoV-2 clearance rate as -0.32 (95% CI, -
268 0.42 to -0.22) \log_{10} copies/ml day⁻¹ (**Figure 4A**). Both estimates were comparable between the
269 sexes for children (**Figure 4D**). The estimated mean duration of URT shedding (down to 0 \log_{10}
270 copies/ml) was 22.6 (95% CI, 17.0-28.1) DFSO for children with COVID-19.

271 Between pediatric cases, who had nonsevere illness in our dataset, and adults with nonsevere
272 illness, both URT shedding at 1 DFSO (P for intercept = 0.653) and URT dynamics (P for
273 interaction = 0.400) were similar (**Figure 4A**). Distributions of rVL were also comparable
274 between these cohorts (**Figure 4B**). Conversely, URT shedding at 1 DFSO was greater for
275 severely affected adults when compared to nonsevere pediatric cases (P for intercept = 0.017),
276 but URT dynamics remained similar (P for interaction = 0.863) (**Figure 4C**).

277

278 **DISCUSSION**

279 Our study systematically developed a dataset of COVID-19 case characteristics and rVLs
280 and conducted stratified analyses on SARS-CoV-2 shedding post-symptom onset. In the URT,
281 we found that adults with severe COVID-19 showed higher rVLs shortly after symptom onset,
282 but similar SARS-CoV-2 clearance rates, when compared with their nonsevere counterparts. In
283 the LRT, we found that high, persistent shedding was associated with severe COVID-19, but not
284 nonsevere illness, in adults. Interestingly, in the analyzed periods, adults with severe disease
285 tended to have higher rVLs in the LRT than the URT.

286 After stratifying for disease severity, we found that sex and age had nonsignificant effects on
287 post-symptom-onset SARS-CoV-2 shedding levels and dynamics for each included analysis
288 (summarized in **Table 2**). Thus, while sex and age influence the tendency to develop severe
289 COVID-19 (2-4), we find no such sex dimorphism or age distinction in URT shedding among
290 cases of similar severity. This includes children, who had nonsevere illness in our study and
291 show similar URT shedding post-symptom onset as adults with nonsevere illness.

292 Notably, our analyses indicate that high, persistent LRT shedding of SARS-CoV-2
293 characterizes severe COVID-19 in adults. This suggests that the effective immune responses
294 associated with milder COVID-19, including innate, cross-reactive and coordinated adaptive
295 immunity (5-9), do not significantly inhibit early, or prolonged, SARS-CoV-2 replication in the
296 LRT of severely affected adults. Hence, uncontrolled LRT replication tends to continue, at least,
297 to 10 DFSO, coinciding with the timing of clinical deterioration (median, 10 DFSO) (2, 49).
298 Furthermore, the bifurcated profiles of LRT shedding concur with the observed severity-
299 associated differences in lung pathology, in which severe cases show hyperinflammation and
300 progressive loss of epithelial-endothelial integrity (50-52).

301 Our results suggest that rVL may be a key prognostic indicator in SARS-CoV-2 infection.
302 They reinforce that severe COVID-19 is associated with greater rVLs than nonsevere illness (12-
303 14), and suggest that sex and age may not significantly influence prognostic thresholds. In the
304 URT, both nonsevere and severe cases tend to clear SARS-CoV-2 at comparable rates. Thus,
305 time course of disease (e.g., DFSO) should be considered alongside rVL, rather than simply
306 employing rVL at admission. LRT shedding, however, bifurcates considerably between
307 nonsevere and severe COVID-19, meaning that SARS-CoV-2 quantitation from the LRT may
308 more accurately predict severity. While URT specimens are typically used to diagnose COVID-
309 19, LRT specimens (our study predominantly analyzed sputum) may be collected from high-risk
310 patients for severity prognostication.

311 While our analyses did not account for virus infectivity, higher SARS-CoV-2 rVL is
312 associated with a higher likelihood of culture positivity, from adults (15, 16) as well as children
313 (36), and higher transmission risk (10). Hence, our results suggest that infectiousness increases
314 with COVID-19 severity, concurring with epidemiological analyses (53, 54). They also suggest
315 that adult and pediatric infections of similar severity have comparable infectiousness, reflecting
316 epidemiological findings on age-based infectiousness (54-56). Moreover, since respiratory
317 aerosols are typically produced from the LRT (57), severe SARS-CoV-2 infections may have
318 increased, and extended, risk for aerosol transmission. As severe cases tend to be hospitalized,
319 this provides one possible explanation for the elevated risk of COVID-19 among healthcare
320 workers in inpatient settings (58); airborne precautions, such as the use of N95 or air-purifying
321 respirators, should be implemented around patients with COVID-19.

322 Our study has limitations. First, while our study design systematically developed a large,
323 diverse dataset, there were few severe female cases with LRT specimens and no severe pediatric

324 cases included. Statistical comparisons involving these cohorts were not conducted based on
325 increased sensitivity to sampling bias, as COVID-19 presents broad heterogeneity in rVL.
326 Additional studies should permit these remaining comparisons. Second, our analyses did not
327 assess the influence of therapies or additional case characteristics, including comorbidities.
328 While the relationships between some comorbidities and SARS-CoV-2 kinetics remain unclear,
329 recent studies indicate many potential therapies (e.g., remdesivir, hydroxychloroquine, lopinavir,
330 ritonavir, low-dose monoclonal antibodies and ivermectin) have no significant anti-SARS-CoV-2
331 effects in patients (59-64). Third, the systematic dataset consisted largely of hospitalized
332 patients, and our results may not generalize to asymptomatic infections.

333 In summary, our findings provide insight into SARS-CoV-2 kinetics and describe
334 virological factors that distinguish severe COVID-19 from nonsevere illness. They show that
335 high, persistent LRT shedding characterizes severe disease in adults, highlighting the potential
336 prognostic utility of SARS-CoV-2 quantitation from LRT specimens. Lastly, each study
337 identified by our systematic review collected specimens before October 2020. As widespread
338 transmission of the emerging variants of concern likely occurred after this date (65, 66), our
339 study presents a quantitative resource to assess the effects of their mutations on respiratory
340 shedding levels and dynamics.

341 **Acknowledgement:** The authors thank S. Fafi-Kremer, PharmD, PhD (Strasbourg University
342 Hospital); Y. Hirotsu, PhD (Yamanashi Central Hospital); M.S. Kelly, MD, MPH (Duke
343 University); E. Lavezzo, PhD, and A. Crisanti, MD, PhD (University of Padova); J.Z. Li, MD,
344 MMSc (Brigham & Women’s Hospital); Cédric Laouénan, MD, PhD, and Yazdan Yazdanpanah,
345 MD, PhD (Bichat-Claude Bernard University Hospital); N.K. Shrestha, MD (Cleveland Clinic);
346 T. Teshima, MD, PhD (Hokkaido University); S. Trouillet-Assant, PhD (Université Hospital of
347 Lyon); J.J.A. van Kampen, MD, PhD (Erasmus University Medical Center); A. Wyllie, PhD, N.
348 Grubaugh, PhD, and A. Ko, MD (Yale School of Public Health); and A. Yilmaz, MD, PhD
349 (Sahlgrenska University Hospital) for responses to data inquiries.

350

351 **Financial support:** This study was supported by NSERC. Mr. Chen was supported by the
352 NSERC Vanier Canada Graduate Scholarship (608544). Dr. Fisman was supported by the
353 Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research Fund, OV4-
354 170360). Dr. Gu was supported by the NSERC Senior Industrial Research Chair.

355

356 **Disclosures:** Dr. Fisman has received honoraria related to work with Pfizer, Astra Zeneca and
357 Seqirus on vaccines for respiratory viruses.

358

359 **Reproducible Research Statement:** *Study protocol, statistical code and data set:* Available
360 from Dr. Gu (e-mail, f.gu@utoronto.ca).

361

362 **Corresponding Author:** Frank X. Gu, PhD, University of Toronto, 200 College St., Toronto,
363 ON M5S 3E5, Canada; e-mail, f.gu@utoronto.ca.

364 References

- 365 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020;20(5):533-4. [PMID: 32087114] doi:10.1016/S1473-3099(20)30120-1
- 366 2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-62. [PMID: 32171076] doi:10.1016/S0140-6736(20)30566-3
- 367 3. Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. *Ann Intern Med.* 2020;173(10):773-81. [PMID: 32783686] doi:10.7326/M20-3742
- 370 4. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA.* 2020;323(18):1775-6. [PMID: 32203977] doi:10.1001/jama.2020.4683
- 371 5. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature.* 2020;588(7837):315-20. [PMID: 32846427] doi:10.1038/s41586-020-2700-3
- 372 6. Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Sci Transl Med.* 2020;12(564). [PMID: 32958614] doi:10.1126/scitranslmed.abd5487
- 373 7. Rydzynski MC, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell.* 2020;183(4):996-1012 e19. [PMID: 33010815] doi:10.1016/j.cell.2020.09.038
- 374 8. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science.* 2020;370(6522):1339-43. [PMID: 33159009] doi:10.1126/science.abe1107
- 375 9. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature.* 2020;584(7821):463-9. [PMID: 32717743] doi:10.1038/s41586-020-2588-y
- 376 10. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis.* 2021. [PMID: 33545090] doi:10.1016/S1473-3099(20)30985-3
- 377 11. Fu Y, Li Y, Guo E, et al. Dynamics and correlation among viral positivity, seroconversion, and disease severity in COVID-19: a retrospective study. *Ann Intern Med.* 2020. [PMID: 33284684] doi:10.7326/M20-3337
- 378 12. Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir Med.* 2020;8(9):e70. [PMID: 32771081] doi:10.1016/S2213-2600(20)30354-4
- 379 13. Westblade LF, Brar G, Pinheiro LC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. *Cancer Cell.* 2020;38(5):661-71 e2. [PMID: 32997958] doi:10.1016/j.ccell.2020.09.007
- 380 14. Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. *Clin Infect Dis.* 2020. [PMID: 32603425] doi:10.1093/cid/ciaa851
- 381 15. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature.* 2020;581(7809):465-9. [PMID: 32235945] doi:10.1038/s41586-020-2196-x
- 382 16. van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun.* 2021;12(1):267. [PMID: 33431879] doi:10.1038/s41467-020-20568-4
- 383 17. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology.* 2020;295(3):200463. [PMID: 32077789] doi:10.1148/radiol.2020200463
- 384 18. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med.* 2020;26(5):672-5. [PMID: 32296168] doi:10.1038/s41591-020-0869-5
- 385 19. Chen PZ, Bobrovitz N, Premji Z, et al. Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols. medRxiv. Preprint posted online 2 December 2020. doi:10.1101/2020.10.13.20212233
- 386 20. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions.* Cochrane book series. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.

- 415 21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses:
416 the PRISMA statement. *PLOS Med.* 2009;6(7):e1000097. [PMID: 19621072]
417 doi:10.1371/journal.pmed.1000097
- 418 22. Han MS, Byun JH, Cho Y, et al. RT-PCR for SARS-CoV-2: quantitative versus qualitative. *Lancet Infect*
419 *Dis.* 2021;21(2):165. [PMID: 32445709] doi:10.1016/S1473-3099(20)30424-2
- 420 23. Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian
421 municipality of Vo'. *Nature.* 2020;584(7821):425-9. [PMID: 32604404] doi:10.1038/s41586-020-2488-1
- 422 24. Warnke P, Warning L, Podbielski A. Some are more equal - a comparative study on swab uptake and
423 release of bacterial suspensions. *PLOS One.* 2014;9(7):e102215. [PMID: 25010422]
424 doi:10.1371/journal.pone.0102215
- 425 25. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva
426 samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
427 *Lancet Infect Dis.* 2020;20(5):565-74. [PMID: 32213337] doi:10.1016/S1473-3099(20)30196-1
- 428 26. Zheng SF, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-
429 CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ.*
430 2020;369:m1443. [PMID: 32317267] doi:10.1136/bmj.m1443
- 431 27. National Institutes of Health. Clinical spectrum of SARS-CoV-2 infection. Accessed at
432 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum> on 1 February 2020.
- 433 28. Bal A, Brengel-Pesce K, Gaymard A, et al. Clinical and microbiological assessments of COVID-19 in
434 healthcare workers: a prospective longitudinal study. medRxiv. Preprint posted online 6 November 2020.
435 doi:10.1101/2020.11.04.20225862
- 436 29. Benotmane I, Gautier-Vargas G, Wendling MJ, et al. In-depth virological assessment of kidney transplant
437 recipients with COVID-19. *Am J Transplant.* 2020;20(11):3162-72. [PMID: 32777130]
438 doi:10.1111/ajt.16251
- 439 30. Biguenet A, Bouiller K, Marty-Quinternet S, et al. SARS-CoV-2 respiratory viral loads and association
440 with clinical and biological features. *J Med Virol.* 2020. [PMID: 32889755] doi:10.1002/jmv.26489
- 441 31. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease
442 severity and mortality. *Nat Commun.* 2020;11(1):5493. [PMID: 33127906] doi:10.1038/s41467-020-
443 19057-5
- 444 32. Han MS, Seong MW, Kim N, et al. Viral RNA load in mildly symptomatic and asymptomatic children
445 with COVID-19, Seoul, South Korea. *Emerg Infect Dis.* 2020;26(10):2497-9. [PMID: 32497001]
446 doi:10.3201/eid2610.202449
- 447 33. Hirotsu Y, Maejima M, Shibusawa M, et al. Comparison of automated SARS-CoV-2 antigen test for
448 COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven
449 serially followed patients. *Int J Infect Dis.* 2020;99:397-402. [PMID: 32800855]
450 doi:10.1016/j.ijid.2020.08.029
- 451 34. Hurst JH, Heston SM, Chambers HN, et al. SARS-CoV-2 infections among children in the biospecimens
452 from respiratory virus-exposed kids (BRAVE Kids) study. *Clin Infect Dis.* 2020. [PMID: 33141180]
453 doi:10.1093/cid/ciaa1693
- 454 35. Iwasaki S, Fujisawa S, Nakakubo S, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab
455 and saliva. *J Infect.* 2020;81(2):e145-e7. [PMID: 32504740] doi:10.1016/j.jinf.2020.05.071
- 456 36. L'Huillier AG, Torriani G, Pigny F, et al. Culture-competent SARS-CoV-2 in nasopharynx of
457 symptomatic neonates, children, and adolescents. *Emerg Infect Dis.* 2020;26(10):2494-7. [PMID:
458 32603290] doi:10.3201/eid2610.202403
- 459 37. Pan Y, Zhang D, Yang P, et al. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis.*
460 2020;20(4):411-2. [PMID: 32105638] doi:10.1016/S1473-3099(20)30113-4
- 461 38. Peng L, Liu J, Xu WX, et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and
462 oropharyngeal swabs specimens. *J Med Virol.* 2020;92(9):1676-80. [PMID: 32330305]
463 doi:10.1002/jmv.25936
- 464 39. Shrestha NK, Marco Canosa F, Nowacki AS, et al. Distribution of transmission potential during
465 nonsevere COVID-19 illness. *Clin Infect Dis.* 2020;71(11):2927-32. [PMID: 32594116]
466 doi:10.1093/cid/ciaa886

- 467 40. Sun J, Tang X, Bai R, et al. The kinetics of viral load and antibodies to SARS-CoV-2. *Clin Microbiol*
468 *Infect.* 2020;26(12):1690 e1- e4. [PMID: 32898715] doi:10.1016/j.cmi.2020.08.043
- 469 41. Vetter P, Eberhardt CS, Meyer B, et al. Daily viral kinetics and innate and adaptive immune response
470 assessment in COVID-19: a case series. *mSphere.* 2020;5(6). [PMID: 33177214]
471 doi:10.1128/mSphere.00827-20
- 472 42. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for
473 detection of SARS-CoV-2. *N Engl J Med.* 2020;383(13):1283-6. [PMID: 32857487]
474 doi:10.1056/NEJMc2016359
- 475 43. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for
476 persistent fecal viral shedding. *Nat Med.* 2020;26(4):502-5. [PMID: 32284613] doi:10.1038/s41591-020-
477 0817-4
- 478 44. Yazdanpanah Y, French COVID cohort investigators and study group. Impact on disease mortality of
479 clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19
480 patients. *J Med Virol.* 2020. [PMID: 33058220] doi:10.1002/jmv.26601
- 481 45. Yilmaz A, Marklund E, Andersson M, et al. Upper respiratory tract levels of Severe Acute Respiratory
482 Syndrome Coronavirus 2 RNA and duration of viral RNA shedding do not differ between patients with
483 mild and severe/critical Coronavirus Disease 2019. *J Infect Dis.* 2021;223(1):15-8. [PMID: 33020822]
484 doi:10.1093/infdis/jiaa632
- 485 46. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric severe acute respiratory syndrome coronavirus 2
486 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. *J Pediatr.* 2020;227:45-52.
487 [PMID: 32827525] doi:10.1016/j.jpeds.2020.08.037
- 488 47. Zhang N, Gong YH, Meng FP, et al. Comparative study on virus shedding patterns in nasopharyngeal and
489 fecal specimens of COVID-19 patients. *Sci China Life Sci.* 2020. [PMID: 32778998]
490 doi:10.1007/s11427-020-1783-9
- 491 48. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected
492 patients. *N Engl J Med.* 2020;382(12):1177-9. [PMID: 32074444] doi:10.1056/NEJMc2001737
- 493 49. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med.* 2020;383(25):2451-60. [PMID:
494 32412710] doi:10.1056/NEJMc2009575
- 495 50. Matheson NJ, Lehner PJ. How does SARS-CoV-2 cause COVID-19? *Science.* 2020;369(6503):510-1.
496 [PMID: 32732413] doi:10.1126/science.abc6156
- 497 51. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the
498 pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res.* 2020;220:1-13. [PMID:
499 32299776] doi:10.1016/j.trsl.2020.04.007
- 500 52. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress
501 syndrome. *Lancet Respir Med.* 2020;8(4):420-2. [PMID: 32085846] doi:10.1016/S2213-2600(20)30076-
502 X
- 503 53. Sayampanathan AA, Heng CS, Pin PH, et al. Infectivity of asymptomatic versus symptomatic COVID-
504 19. *Lancet.* 2021;397(10269):93-4. [PMID: 33347812] doi:10.1016/S0140-6736(20)32651-9
- 505 54. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and
506 infectivity in Wuhan: a retrospective observational study. *Lancet Infect Dis.* 2021. [PMID: 33476567]
507 doi:10.1016/S1473-3099(20)30981-6
- 508 55. Sun K, Wang W, Gao L, et al. Transmission heterogeneities, kinetics, and controllability of SARS-CoV-
509 2. *Science.* 2021;371(6526). [PMID: 33234698] doi:10.1126/science.abe2424
- 510 56. Laxminarayan R, Wahl B, Dudala SR, et al. Epidemiology and transmission dynamics of COVID-19 in
511 two Indian states. *Science.* 2020;370(6517):691-7. [PMID: 33154136] doi:10.1126/science.abd7672
- 512 57. Johnson GR, Morawska L, Ristovski ZD, et al. Modality of human expired aerosol size distributions. *J*
513 *Aerosol Sci.* 2011;42(12):839-51. [PMID: 20923611] doi:10.1016/j.jaerosci.2011.07.009
- 514 58. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and
515 the general community: a prospective cohort study. *Lancet Public Health.* 2020;5(9):E475-E83. [PMID:
516 32745512] doi:10.1016/S2468-2667(20)30164-X
- 517 59. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind,
518 placebo-controlled, multicentre trial. *Lancet.* 2020;395(10236):1569-78. [PMID: 32423584]
519 doi:10.1016/S0140-6736(20)31022-9

- 520 60. Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of
521 efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. *Nat Commun.*
522 2020;11(1):5284. [PMID: 33082342] doi:10.1038/s41467-020-19056-6
- 523 61. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with
524 Covid-19. *N Engl J Med.* 2021;384(3):229-37. [PMID: 33113295] doi:10.1056/NEJMoa2029849
- 525 62. Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral
526 load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind,
527 placebo-controlled, randomized clinical trial. *EClinicalMedicine.* 2021:100720. [PMID: 33495752]
528 doi:10.1016/j.eclinm.2020.100720
- 529 63. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.
530 *N Engl J Med.* 2020;382(19):1787-99. [PMID: 32187464] doi:10.1056/NEJMoa2001282
- 531 64. World Health Organization Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 -
532 interim WHO Solidarity trial results. *N Engl J Med.* 2021;384(6):497-511. [PMID: 33264556]
533 doi:10.1056/NEJMoa2023184
- 534 65. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and severity of novel SARS-CoV-2
535 variant of concern 202012/01 in England. *medRxiv.* Preprint posted online 7 February 2021.
536 doi:10.1101/2020.12.24.20248822
- 537 66. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute
538 respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in
539 South Africa. *medRxiv.* Preprint posted online 22 December 2020. doi:10.1101/2020.12.21.20248640
540

541 **Table 1.** Characteristics of adult and pediatric COVID-19 cases

	Adult	Pediatric
Cases, <i>n</i>	1 266	136
URT specimens, <i>n</i>	1 513	192
LRT specimens, <i>n</i>	210	0
Mean age (SD), <i>y</i>	51.8 (18.0)	8.7 (5.3)
Male, <i>n (%)</i>	528 (44.0)	63 (52.5)
Disease severity, <i>n (%)</i>		
Asymptomatic	2 (0.2)	5 (3.7)
Mild	710 (57.5)	112 (83.6)
Moderate	178 (14.4)	17 (12.7)
Severe	167 (13.5)	0 (0.0)
Critical	178 (14.4)	0 (0.0)

542 LRT = lower respiratory tract; URT = upper respiratory tract.

543 The table summarizes collected case characteristics in the systematic dataset. Adult cases were

544 those aged 18 y or older, while pediatric cases were those aged younger than 18 y.

545 **Table 2.** Summary of statistical comparisons on SARS-CoV-2 shedding, across the respiratory
 546 tract, COVID-19 severity, sex and age cohorts

Group 1	Group 2	P value*	
		Intercept†	Interaction‡
URT, ≥18 y			
Nonsevere	Severe	0.005*	0.479
Female (nonsevere)	Male (nonsevere)	0.085	0.644
Female (severe)	Male (severe)	0.326	0.280
Nonsevere (18-59 y)	Nonsevere (≥60 y)	0.294	0.100
Severe (18-59 y)	Severe (≥60 y)	0.915	0.359
LRT, ≥18 y §			
Nonsevere	Severe	0.006*	0.053
Severe (18-59 y)	Severe (≥60 y)	0.745	0.716
URT vs. LRT, ≥18 y			
Nonsevere (URT, ≥18 y)	Nonsevere (LRT, ≥18 y)	0.651	0.231
Severe (URT, ≥18 y)	Severe (LRT, ≥18 y)	0.031*	0.151
URT, 0-17 y			
Nonsevere (0-17 y)	Nonsevere (≥18 y)	0.653	0.400
Nonsevere (0-17 y)	Severe (≥18 y)	0.017*	0.863
Female (nonsevere)	Male (nonsevere)	0.667	0.333

547 COVID-19 = coronavirus disease 2019; DFSO = days from symptom onset; LRT = lower

548 respiratory tract; nonsevere = asymptomatic, mild and moderate COVID-19; rVL = respiratory

549 viral load; severe = severe and critical COVID-19; URT = upper respiratory tract.

550

551 * $P < 0.05$. Each regression analysis was shown in **Figures 2 to 4**.

552 † P value for the intercept in regression analysis compares the mean rVLs at 1 DFSO for the


553 URT or, for any analyses including the LRT, at 4 DFSO.

554 ‡ P value for interaction in regression analysis describes the difference in respiratory shedding

555 dynamics along the time course of disease.


556 § There were small sample sizes in the nonsevere cohorts and female (LRT, severe, ≥18 y)

557 cohort, and these analyses were not included.



558

559 *Figure 1.* Study selection.



560

561 **Figure 2.** Comparison of SARS-CoV-2 shedding in the adult URT, across disease severity, sex
 562 and age cohorts.


563

564 COVID-19 = coronavirus disease 2019; DFSO = days from symptom onset; nonsevere =
 565 asymptomatic, mild and moderate COVID-19; rVL = respiratory viral load; SARS-CoV-2 =
 566 severe acute respiratory syndrome coronavirus 2; severe = severe and critical COVID-19; URT =
 567 upper respiratory tract.

568

569 **A and B.** Regression analysis (A) and estimated distributions at 2, 4, 7 and 10 DFSO (B) of URT
 570 shedding for severe and nonsevere adult (aged 18 y or older) COVID-19. Arrows denote rVLs
 571 for the 80th case percentiles, in terms of rVL, for each age group. **C and D.** Regression analyses
 572 comparing URT shedding between sexes for nonsevere (C) and severe (D) adult COVID-19. **E**
 573 and **F.** Regression analyses comparing URT shedding between age cohorts (aged 18-59 y and 60

574 y or older) for nonsevere (E) and severe (F) adult COVID-19. Open circles represent rVL data
575 and were offset from their DFSO for visualization. Lines and bands show regressions and their
576 95% CIs, respectively. *P* values for the intercept compare the rVLs at 1 DFSO. *P* values for
577 interaction compare shedding dynamics.



578

579 **Figure 3.** Comparison of SARS-CoV-2 shedding in the adult LRT, across disease severity, age
580 and with shedding in the adult URT.

581

582 COVID-19 = coronavirus disease 2019; DFSO = days from symptom onset; LRT = lower

583 respiratory tract; nonsevere = asymptomatic, mild and moderate COVID-19; rVL = respiratory

584 viral load; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; severe = severe and

585 critical COVID-19; URT = upper respiratory tract.

586


587 **A and B.** Regression analysis (A) and estimated distributions at 6, 8 and 10 DFSO (B) of LRT

588 shedding for severe and nonsevere adult (aged 18 y or older) COVID-19. Arrows denote rVLs

589 for the 80th case percentiles, in terms of rVL, for each age group. **C.** Regression analyses

590 comparing LRT shedding between age cohorts (aged 18-59 y and 60 y or older) for severe adult

591 COVID-19. **D** and **E**. Regression analyses comparing URT and LRT shedding for nonsevere (D)
592 and severe (E) adult COVID-19. Open circles represent rVL data and were offset from their
593 DFSO for visualization. Lines and bands show regressions and their 95% CIs, respectively. *P*
594 values for the intercept compare the rVLs at 4 DFSO. *P* values for interaction compare shedding
595 dynamics.



596

597 **Figure 4.** URT shedding of SARS-CoV-2 in pediatric COVID-19, compared with adults and
598 across sex.

599

600 COVID-19 = coronavirus disease 2019; DFSO = days from symptom onset; nonsevere =
601 asymptomatic, mild and moderate COVID-19; rVL = respiratory viral load; SARS-CoV-2 =
602 severe acute respiratory syndrome coronavirus 2; severe = severe and critical COVID-19; URT =
603 upper respiratory tract.

604

605 **A and B.** Regression analysis (A) and estimated distributions at 2, 6, and 10 DFSO (B) of URT
606 shedding for children (aged 0-17 y) with nonsevere COVID-19 and adults (aged 18 y or older)
607 with nonsevere illness. Arrows denote rVLs for the 80th case percentiles, in terms of rVL, for
608 each cohort. **C.** Regression analysis comparing URT shedding between nonsevere pediatric and

609 severe adult COVID-19. **D.** Regression analysis comparing URT shedding between sexes for
610 pediatric cases. Open circles represent rVL data and were offset from their DFSO for
611 visualization. Lines and bands show regressions and their 95% CIs, respectively. *P* values for the
612 intercept compare the rVLs at 1 DFSO. *P* values for interaction compare shedding dynamics.